Clinical Trial

Association of TNFAIP3 With Immune-mediated TTP

Study acronym: A20iTTP
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 27, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to investigate whether genetic variation in the TNFAIP3 locus is associated with immune-mediated thrombotic thrombocytopenic purpura (iTTP), and whether such association is mediated by decreased expression of A20 (TNFAIP3). The study includes a case-control design to assess genotype-expression association and a cohort study to evaluate clinical outcomes such as disease relapse.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-07.
Status change: Active, Not Recruiting → Recruiting 2026-03-26
Trial Details
NCT Number NCT06928233
Lead Sponsor Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Conditions Thrombotic Thrombocytopenic Purpura, Acquired
Enrollment 400 participants
Start Date 2025-04-07
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-27